Quick Answer
MoonLake Immunotherapeutics reported Common Stock Shares Outstanding of 52.70 million shares for the year ending 2022.
- This data is from MoonLake Immunotherapeutics's annual report (Form 10-K), filed with the SEC on February 26, 2025.
- XBRL data for this metric is available from 2022 to 2022 (1 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: